

## **AMENDMENTS TO SPECIFICATIONS**

Please replace paragraph [0116] of the published application as follows:

- - The peptide of SEQ ID NO:4 was shown to be as active as the native CNP1-22, SEQ ID NO:1. The modification lies in the removal of the N-terminal amino acids, the ectocyclic part of the peptide. The peptide of SEQ ID NO: 10 contains a substitution of Met17 with Ala. This variant retains high activity perhaps due to the alteration of an NEP cleavage site. Furthermore, the peptide of SEQ ID NO:10 was tested in bone culture and shown to induced elongation of Ach369 femora even at a concentration similar to that of CNP. - -